Primary Tumor Biology, Recurrence and Survival After Colorectal Liver Metastasis Resection: The BIO-CRLM Study

OBJECTIVE: To evaluate whether integrated primary tumor biology, combining primary tumor location and RAS/BRAF status, defines recurrence phenotypes and survival trajectories after liver resection for colorectal liver metastases (CRLM). SUMMARY BACKGROUND DATA: Selection for resection remains largely morphology-based, although tumor biology strongly influences post-hepatectomy outcomes. Primary tumor site and RAS/BRAF status are individually prognostic, but whether their integration identifies distinct post-resection trajectories is unclear. METHODS: An international multicenter cohort of patients undergoing liver resection for CRLM between 2017 and 2023 was analyzed. Integrated biology was defined a priori as left-sided-wild-type, right-sided-wild-type, rectal-wild-type, left-sided-RAS-mutant, right-sided-RAS-mutant, rectal RAS-mutant, and BRAF-mutant disease. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcomes included early recurrence, disseminated first recurrence, and first recurrence phenotype. RESULTS: Among 3162 patients from 44 centers, 2415 (76.4%) developed recurrence and 1342 (42.4%) died. Integrated biology was independently associated with both RFS and OS (global P<0.001 for both). Compared with left-WT tumors, the highest mortality risks were observed in BRAF-mutant disease [hazard ratio (HR): 2.68, 95% CI: 2.02-3.57, P<0.001] and right-RAS-mutant disease (HR: 2.32, 95% CI: 1.94-2.79, P<0.001). Integrated biology was also associated with early recurrence, disseminated first recurrence, and first recurrence phenotype. Rectal-RAS-mutant tumors had the strongest association with lung-only recurrence [relative risk ratio (RRR): 3.38, 95% CI: 2.22-5.13, P<0.001] and disseminated recurrence (RRR: 2.57, 95% CI: 1.86-3.55, P<0.001) relative to liver-only recurrence. CONCLUSIONS: Integrated primary tumor biology identifies clinically distinct post-hepatectomy disease trajectories after CRLM resection. Combining primary tumor site with RAS/BRAF status may support preoperative counseling, surveillance planning, and trial stratification.

Authors

Institutions

Publication Details

Journal
Annals of Surgery
Published
2026-11-13
DOI
https://doi.org/10.1097/sla.0000000000007261
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Primary Tumor Biology, Recurrence and Survival After Colorectal Liver Metastasis Resection: The BIO-CRLM Study

Ioannis Gkekas, Mario Serradilla‐Martín, Patrick P. Starlinger, Ryan P. Merkow et al.
1 links
Annals of Surgery
Colorectal Cancer Treatments and Studies
article

Primary Tumor Biology, Recurrence and Survival After Colorectal Liver Metastasis Resection: The BIO-CRLM Study

Ioannis Gkekas, Mario Serradilla‐Martín, Patrick P. Starlinger, Ryan P. Merkow, Koroush Shahsavar Haghighi, Alex Nicolas Gordon-Weeks, Steven A White, Malin Sternby Eilard, Thomas Gruenberger, Olivier Detry, Laurent Sulpice, Réza Kianmanesh, Dhiresh Kumar Maharjan, Ernesto Sparrelid, Marcello Maestri, Dimitrios D. Karavias, Brian Ritchie Davidson, Cornelius A. Thiels, Brian K. P. Goh, Bergþór Björnsson, Lawrence O’Leary, Görkem Uzunyolcu, Dhanny Gomez, Jennie Engstrand, Jörg Kleeff, Ricky Harminder Bhogal, Jane McClements, Marco Gerling, Belén Conde Inarejos, Prabin Bikram Thapa, Jon Unosson, Derek Manas, John Barry Conneely, Danijel A. Galun, Baki Türkoğlu, Abdullah Khalid Malik, Bodil Andersson, Gregor Alexander Stavrou, Ambareen Kausar, Yuki Hirose, Samuel James Tingle, Nicola de Liguori Carino, Eric Herrero Fonollosa, John S. Hammond, Karin U. Johansen, Anita Balakrishnan, Nehal Shah, Neil Bhardwaj, Hassan Malik, J. Michael Millis, Andrew J. Healey, José Manuel Ramia, Vanja Podrascanin, Eva Maier, Artur Rebelo, Noah Cohen, Sanjay Pandanaboyana, Priyal Patel, Maximiliano Gelli, Enrico Prosperi, Pietro Addeo, Moritz Bergmann, KT Derek Yeung, James Oh Park, Andrew Gumbs, Pietro Matucci
article en

Abstract

OBJECTIVE: To evaluate whether integrated primary tumor biology, combining primary tumor location and RAS/BRAF status, defines recurrence phenotypes and survival trajectories after liver resection for colorectal liver metastases (CRLM). SUMMARY BACKGROUND DATA: Selection for resection remains largely morphology-based, although tumor biology strongly influences post-hepatectomy outcomes. Primary tumor site and RAS/BRAF status are individually prognostic, but whether their integration identifies distinct post-resection trajectories is unclear. METHODS: An international multicenter cohort of patients undergoing liver resection for CRLM between 2017 and 2023 was analyzed. Integrated biology was defined a priori as left-sided-wild-type, right-sided-wild-type, rectal-wild-type, left-sided-RAS-mutant, right-sided-RAS-mutant, rectal RAS-mutant, and BRAF-mutant disease. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcomes included early recurrence, disseminated first recurrence, and first recurrence phenotype. RESULTS: Among 3162 patients from 44 centers, 2415 (76.4%) developed recurrence and 1342 (42.4%) died. Integrated biology was independently associated with both RFS and OS (global P<0.001 for both). Compared with left-WT tumors, the highest mortality risks were observed in BRAF-mutant disease [hazard ratio (HR): 2.68, 95% CI: 2.02-3.57, P<0.001] and right-RAS-mutant disease (HR: 2.32, 95% CI: 1.94-2.79, P<0.001). Integrated biology was also associated with early recurrence, disseminated first recurrence, and first recurrence phenotype. Rectal-RAS-mutant tumors had the strongest association with lung-only recurrence [relative risk ratio (RRR): 3.38, 95% CI: 2.22-5.13, P<0.001] and disseminated recurrence (RRR: 2.57, 95% CI: 1.86-3.55, P<0.001) relative to liver-only recurrence. CONCLUSIONS: Integrated primary tumor biology identifies clinically distinct post-hepatectomy disease trajectories after CRLM resection. Combining primary tumor site with RAS/BRAF status may support preoperative counseling, surveillance planning, and trial stratification.

Annals of Surgery
Linköping University (SE), Uppsala University (SE), Belfast Health and Social Care Trust (GB), University of Udine (IT), University of Vienna (AT), Mount Sinai Hospital (US), Mayo Clinic (US), Nottingham University Hospitals NHS Trust (GB), Institute of Cancer Research (GB), Innsbruck Medical University (AT), University of Liège (BE), Universidad de Granada (ES), Lund University (SE), Universität Innsbruck (AT), Singapore General Hospital (SG), University of Pavia (IT), Aintree University Hospitals NHS Foundation Trust (GB), Leicester Royal Infirmary (GB), Sahlgrenska University Hospital (SE), The Royal Free Hospital (GB), Newcastle upon Tyne Hospitals NHS Foundation Trust (GB), Institut Gustave Roussy (FR), Freeman Hospital (GB), Manchester Royal Infirmary (GB), Cambridge University Hospitals NHS Foundation Trust (GB), Christchurch Hospital (NZ), Edinburgh Royal Infirmary (GB), University Hospital Southampton NHS Foundation Trust (GB), Mater Misericordiae University Hospital (IE), Karolinska Institutet (SE), Université Rennes 2 (FR), UNSW Sydney (AU), University of Oxford (GB), University of Chicago (US), University of Belgrade (RS), NYU Langone Health (US), Aintree University Hospital (GB), Manchester University NHS Foundation Trust (GB), Region Västra Götaland (SE), University Hospital Mútua de Terrassa (ES), Assistance Publique – Hôpitaux de Paris (FR), Sheffield Teaching Hospitals NHS Foundation Trust (GB), Centre Hospitalier Universitaire de Reims (FR), Univerzitetski Klinički Centar Srbije (RS), Instituto de Investigación Biosanitaria de Granada (ES), St. Vincent's University Hospital (IE), Hospital Universitario Virgen de las Nieves (ES), Kepler Universitätsklinikum (AT), Royal Marsden Hospital (GB), Mútua Terrassa (ES), Centre Hospitalier Universitaire de Liège (BE), Skåne University Hospital (SE), Hôpitaux Universitaires de Strasbourg (FR), Oxford University Hospitals NHS Trust (GB), Hôpital Antoine-Béclère (FR), University Hospital in Halle (DE), Klinikum Saarbrücken (DE), Hôpital d'Hautepierre (FR), Royal Blackburn Teaching Hospital (GB), Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (ES), Region Östergötland (SE), Universitätsklinikum Wiener Neustadt (AT), Fondation Gustave Roussy (FR), Université de Rennes (FR), Istanbul University (TR), Université de Strasbourg (FR), Niigata University (JP), Medical University of Vienna (AT), Kathmandu Medical College Teaching Hospital (NP), Newcastle University (GB), University of Gothenburg (SE), Umeå University (SE), University of Sheffield (GB), University of Bologna (IT), Université de Reims Champagne-Ardenne (FR), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon